System for efficient helper-dependent minimal adenovirus construction and rescue

Human Gene Therapy

Volumn 12, Issue 6, 2001, Pages 643-657

  Hillgenberg, M ^a,b   Schnieders, F ^b,c   Loser P ^a   Strauss, M ^b  

^a DeveloGen AG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENDONUCLEASE; VIRUS VECTOR;

ARTICLE; CLONING VECTOR; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; DNA VECTOR; EMBRYO; GENE CASSETTE; GENE EXPRESSION; GENE INSERTION; GENE THERAPY; HUMAN; HUMAN CELL; LONG TERMINAL REPEAT; NONHUMAN; TRANSGENE; VIRUS GENOME; X CHROMOSOME;

ADENOVIRUSES, HUMAN; CELLS, CULTURED; CLONING, MOLECULAR; COSMIDS; DNA PRIMERS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELPER VIRUSES; HUMANS; KANAMYCIN KINASE; LAC OPERON; LUCIFERASES; TRANSGENES; VIRUS REPLICATION; X CHROMOSOME;

ADENOVIRIDAE; ESCHERICHIA COLI;

EID: 0035831605     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401300057342     Document Type: Article

References (85)

1. Complementation of helper-dependent adenoviral vectors: Size effects and titer fluctuations
2. Characterization of an adenovirus gene transfer vector containing an E4 deletion
3. Adenovirus vectors for gene delivery
4. Generation of adenovirus by transfection of plasmids
5. Template requirements for in vivo replication of adenovirus DNA
6. Packaging capacity and stability of human adenovirus type 5 vectors
7. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
8. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4
9. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
10. Decreased cytomegalovirus expression following proinflammatory cytokine treatment of primary human astrocytes
11. Persistence in muscle of an adenoviral vector that lacks all viral genes
12. DNA from both high-capacity and first-generation adenoviral vectors remain intact in skeletal muscle
13. Production and characterization of human 293 cells expressing the site-specific recombianse Cre
14. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
15. Cosmids: A type of plasmid gene-cloning vector that is packageable in vitro in bacteriophage lambda heads
16. Recombinational construction in Escherichia coli of infectious adenoviral genomes
17. New tools for the generation of E1 and/or E3-substituted adenoviral vectors
18. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses
19. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver
20. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs
21. Recombinant adenovirus deleted for all viral genes for gene therapy of cystic fibrosis
22. Use of the cosmid adenoviral vector system for the in vitro construction of recombinant adenoviral vectors
23. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy
24. Transfer of the CTFR gene to the lung of non-human primates with E1-deleted, E2a-defective recombinant adenoviruses: A preclinical toxicology study
25. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy
26. Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant
27. Cis and trans requirements for the selective packaging of adenovirus type 5 DNA
28. Covalently closed circles of human adenovirus DNA are infectious
29. Characteristics of a human cell line transformed by DNA from a human adenovirus type 5
30. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting
31. In vivo expression of full-length human dystrophin from adenoviral vectors deleted for all viral genes
32. Rescue of functional replication origins from embedded configurations in a plasmid carrying the adenovirus genome
33. Construction of adenovirus vectors through Cre/lox-recombination
34. Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promotor
35. Improved production of gutted adenovirus in cells expressing adenovirus terminal protein and DNA polymerase
36. Frequency and stability of chromosomal integration of adenovirus vectors
37. The origin of adenovirus DNA replication: Minimal DNA sequence requirements in vivo
38. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurence
39. Selective extraction of polyoma DNA from infected mouse cell cultures
40. In vitro packaging of lambda and cosmid DNA
41. Isolation of deletion and substitution mutants of adenovirus type 5
42. Long term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector
43. A simple and efficient method for purification of infectious recombinant adenovirus
44. Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses?
45. A 900-kb cosmid contig and 10 new transcripts within the candidate region for myotubular myopathy (MTM1)
46. High capacity adenoviral vectors for gene transfer and somatic gene therapy
47. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase
48. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs
49. Mechanisms and therapeutic applications of immune stimulatory CpG DNA
50. Development of cell lines capable of complementing E1, E4 and protein IX defective ade-novirus type 5 mutants
51. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells
52. Evaluation of HBV promoters for use in hepatic gene therapy
53. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
54. The polypeptides of adenovirus. I. Evidence for multiple components in the virion and a comparision of types 2, 7A, and 12
55. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5
56. Rescue, propagation and partial purification of a helper-dependent adenovirus vector
57. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome
58. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method
59. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors
60. Purification and characterization of the in vitro activity of I-SceI, a novel and highly specific endonuclease encoded by a group I intron
61. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors
62. 1-antitrypsin with negligible toxicity
63. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
64. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
65. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium
66. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging
67. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
68. Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors
69. Construction of a helper-dependent adenoviral vector containing full-length mouse utrophin cDNA
70. Bicistronic vector for the creation of stable mammalian cell lines that predispose all antibiotic-resistant cells to express recombinant protein
71. Optimization of the helper-dependent adenovirus system for production and potency in vivo
72. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
73. Bipartite structure and functional independence of adenovirus type 5 packaging elements
74. Constructing adenoviral vectors by using a circular form of the adenoviral genome cloned in a cosmid and the Cre-lox Precombination system
75. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions
76. Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector
77. Bacteriophage lambda vectors for DNA cloning
78. MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1 deleted recombinant adenoviruses
79. Cellular immunity to viral antigens limits E1-deleted recombinant adenoviruses for gene therapy
80. Inactivation of E2a in recombinant adenoviruses limits the cellular immunity and improves the prospect for gene therapy of cystic fibrosis
81. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
82. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit
83. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A
84. Development of a complementing cell line and a system for construction of adenoviral vectors deleted for E1 and E2a